These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1042 related articles for article (PubMed ID: 28813410)

  • 21. Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
    Kdimati S; Christoph C; Glass Ä; Engel N; Dräger DL; Maletzki C; Becker AS; Zimpfer A
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
    Liu Y; Li X; Zhang H; Zhang M; Wei Y
    Oncogene; 2021 Mar; 40(12):2230-2242. PubMed ID: 33649535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of CMTM6 protein in hepatocellular carcinoma involving the regulation of the immune microenvironment.
    Wei Z; Guo X; Li D; Wang J; Lin C; Tan C; Wang Y; Zhu X; Tan S
    Int J Biol Macromol; 2024 Aug; 275(Pt 2):133618. PubMed ID: 38971275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
    Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
    Gao F; Chen J; Wang J; Li P; Wu S; Wang J; Ji Y
    Biochem Biophys Rep; 2019 Dec; 20():100690. PubMed ID: 31646201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
    Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
    Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade.
    Zhao W; Zhao F; Yang K; Lu Y; Zhang Y; Wang W; Xie H; Deng K; Yang C; Rong Z; Hou Y; Li K
    J Cell Biochem; 2019 Aug; 120(8):13330-13341. PubMed ID: 30916827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
    Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
    J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of BCLAF-1 in PD-L1 stabilization in response to ionizing irradiation.
    Ma Z; Wang H; Meng F; Han Y; Chen Y; Xiao M; Jiang H; Yu Z; Xu B
    Cancer Sci; 2021 Oct; 112(10):4064-4074. PubMed ID: 34251713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
    Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
    BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CMTM6: increased circulating level and up-regulated expression in labial salivary glands in patients with primary Sjogren's syndrome.
    Qian S; Xu J; Zhao S; Yang P; Yang C
    Clin Exp Immunol; 2022 Jan; 207(1):65-71. PubMed ID: 35020842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
    Zeisbrich M; Chevalier N; Sehnert B; Rizzi M; Venhoff N; Thiel J; Voll RE
    Front Immunol; 2021; 12():673912. PubMed ID: 34108971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence.
    Muranushi R; Araki K; Yokobori T; Chingunjav B; Hoshino K; Dolgormaa G; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Harimoto N; Shimoda Y; Sano R; Oyama T; Saeki H; Shirabe K
    Cancer Sci; 2021 Aug; 112(8):3314-3323. PubMed ID: 34080242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and Clinical Significance of
    Shi S; Ma HY; Sang YZ; Ju YB; Liu XY; Zhang ZG
    Biomed Res Int; 2022; 2022():8118909. PubMed ID: 35845949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MARVEL domain containing CMTM4 affects CXCR4 trafficking.
    Bona A; Seifert M; Thünauer R; Zodel K; Frew IJ; Römer W; Walz G; Yakulov TA
    Mol Biol Cell; 2022 Nov; 33(13):ar116. PubMed ID: 36044337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer.
    Lu ZM; Pan SL; Yuan WL; Feng JL; Tian D; Shang XQ
    Medicine (Baltimore); 2023 Dec; 102(50):e36480. PubMed ID: 38115316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.
    Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z
    Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
    Xu L; Zhang Y; Tian K; Chen X; Zhang R; Mu X; Wu Y; Wang D; Wang S; Liu F; Wang T; Zhang J; Liu S; Zhang Y; Tu C; Liu H
    J Exp Clin Cancer Res; 2018 Oct; 37(1):261. PubMed ID: 30373602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
    Zhang C; Zhao S; Wang X
    Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells.
    Gohara Y; Tomonobu N; Kinoshita R; Futami J; Audebert L; Chen Y; Komalasari NLGY; Jiang F; Yoshizawa C; Murata H; Yamamoto KI; Watanabe M; Kumon H; Sakaguchi M
    J Mol Med (Berl); 2023 Apr; 101(4):431-447. PubMed ID: 36869893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.